# Task 1 Preference Label - Transcript A vs B (workspace backup)

Stage: Step 15 Preference Labeling (Healthcare_247_Merrow Task 1, batch 20260606_163720).
Current status: historical backup. Preference Labeling, downstream checks, and final human review are now complete.
Studio-selected pair:
- Transcript A = 0.900 (run a9881c8c-a572-4ab4-bcf9-591a5e7cff3f), 40 steps, 8 pages.
- Transcript B = 0.970 (run a1c6c072-2e61-436b-b6c2-aa74e0861677), 33 steps.
Both deliverables read in full against golden-response-task1-v6.docx before labeling.

KEY FINDING (verified from both shipped docs, not build logs): both attempts are clinically correct on every high-risk decision and neither falls for a planted trap. Both decline the nitrofurantoin switch and keep cefpodoxime, both decline the potassium salt substitute as a hyperkalemia hazard, both defer the home-dose sacubitril/valsartan restart to staged outpatient sequencing, both keep all held cardiorenal agents (neither drops metformin), neither fabricates a culture result, and BOTH correctly refuse to write prednisone 5 mg as a verified dose (A bridges at the interim inpatient dose and says "do not assert 5 mg daily"; B says "does not confirm that dose" and defers the number to rheumatology). Prednisone is NOT the differentiator here - that was the 0.78 run in the FA, a different trajectory. The gap is polish/clarity only; no clinical-correctness gap and no error in A.

VERDICT: B1 (B slightly better). Button = plain "B" (no plus signs). NOT B+ (that is B2 and would overstate the gap).

## Justification (paste-ready, em-dash-free)

Scale Selection: B1 (B slightly better).

Justification: Both attempts are clinically correct on every high-risk decision in this case and neither falls for a planted trap, so the gap is narrow. B edges ahead on the clarity and discipline of its medication-safety write-up, not on catching anything A missed. The decision comes down to how cleanly each handles the prednisone provenance and how usable the final note is at the bedside, where B is marginally tighter.

Prompt adherence: Both deliver what the prompt asked, a disposition-organized reconciliation, co-signable by pharmacy and the hospitalist, that addresses each pharmacy handoff recommendation point by point and includes the discharge antibiotic rather than only the chronic medications. Neither omits the antibiotic. This dimension is a tie.

Correctness: Both are accurate against the chart and reach the same safe conclusions. Both decline the nitrofurantoin switch and continue cefpodoxime, citing the systemic urinary source and the eGFR of 40 to 50; both decline the potassium-based salt substitute as an exogenous potassium load given CKD stage 3 and the pending cardiorenal restarts; both defer the home-dose sacubitril/valsartan restart to a staged, monitored outpatient pathway consistent with nephrology; and both correctly treat the prednisone home dose as unverified, declining to write 5 mg daily off the most recent fill. Neither asserts adrenal insufficiency as proven and neither fabricates a culture result. There is no correctness win for either side.

Completeness: Both cover the full reconciliation, keep all held cardiorenal agents on the list with reassessment plans rather than dropping any, keep inpatient correctional lispro out of the home regimen, and turn the documented functional and medication-management risk into a follow-up plan. B is slightly more complete on the steroid-safety margin, adding the concrete step of having the family quarantine the older prednisone bottles with conflicting taper directions to prevent label-versus-actual confusion at home. A covers the same ground without that specific touch. No material finding is missing from either.

Methodology: Both work from the chart rather than the handoff and adjudicate each recommendation against the record. A reasons sharply that the potassium improvement was achieved while the potassium-sparing agents were held and so is not evidence they can be restarted safely, which is a genuine strength. B frames the prednisone disposition slightly more crisply, stating plainly that the reconciliation does not confirm the dose and deferring the numeric taper to rheumatology, where A reaches the same disposition through a less direct partially-adopt framing. The methodologies are equally sound; the difference is presentation, not approach.

Quality and clarity: This is what decides it. Both are well organized and physician-facing, but B reads as the tighter, more directly co-signable note, with cleaner disposition language on the contested items, while A, though equally correct, is slightly more verbose and frames the prednisone decision less crisply. For a covering hospitalist signing at the bedside, B is marginally easier to act on. That narrow clarity edge is the basis for B1.

## Guardrails (must survive any edit)
1. No sentence names a clinical error in A (there is none).
2. Prednisone stated as handled correctly by BOTH (do not reuse the FA's prednisone-failure framing; that was the 0.78 run).
3. Strongest word for the gap stays "marginally" / "slightly" - this is B1, not B2.

## Submit mechanics
Historical submit mechanics: select plain B -> paste justification into Comments -> Submit Preference -> confirm entry shows in submission history -> run Preference Labels AutoQC. This sequence is complete; this file is preserved as the workspace backup.
